Speaker illustration

Doctor Robert Giugliano

Brigham and Women's Hospital, Boston (United States of America)

Dr Robert P. Giugliano is a Sr Investigator with the TIMI Study Group, Physician in the CV Division at Brigham and Women’s Hospital, Professor of Medicine at Harvard Medical School, Boston, USA. He graduated summa cum laude, phi beta kappa from Dartmouth College. He received his medical degree at Harvard Medical School. He completed his internship, residency and chief residency at Cedars-Sinai Medical Centre, Los Angeles, USA, and a Cardiology Fellow at Massachusetts General Hospital, USA. His research interests are novel lipid-lowering therapies, antithrombotic therapies for afib and ACS, and assessment of outcomes in patients with ACS. Dr Giugliano has authored more than 300 original articles, 200 reviews/editorials/book chapters, and serves on editorial boards. He is the Principal TIMI Inv for 11 clinical trials including the ENGAGE AF-TIMI 48 trial with edoxaban, EC member of several trials including IMPROVE-IT, FOURIER, VESALIUS-CV, and AZALEA-TIMI 71 trials.

Lipids - Drug therapy 2

Event: ESC Congress 2022

Topic: Drug therapy

Session type: Moderated ePosters


Lipid-lowering by PCSK9 modulation: what’s new?

Event: ESC Congress 2022

Topic: Lipid-Lowering Agents

Session type: Abstract Sessions


Anticoagulation in elderly atrial fibrillation patients: clinical considerations and unmet needs

Event: ESC Congress 2020

Topic: Prevention

Session type: Industry Q&A session


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb